GlassScriptPhysician profile
April P Jones
NPI 1649629791
$3,787.25
in general payments reported to CMS, 2019-2025
21 companies · $879 in 2025
The $879 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $219 · 2021: $437 · 2022: $1,105 · 2023: $331 · 2024: $282 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $838.96 | 2021-2025 | Rocklatan, Rhopressa, Tryptyr |
| Sun Pharmaceutical Industries INC. | $480.44 | 2019-2023 | Cequa |
| Allergan, INC. | $341.87 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $327.50 | 2019-2020 | |
| Oyster Point Pharma, INC. | $310.12 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $286.29 | 2024-2025 | |
| Johnson & Johnson Vision Care, INC. | $236.88 | 2022 | |
| Sight Sciences, INC. | $147.09 | 2022 | |
| Glaukos Corporation | $132.88 | 2022-2024 | Ce-Marked Kxla System |
| Biotissue Holdings INC. | $122.79 | 2022 | |
| Astellas Pharma US INC | $94.73 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $85.80 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $85.29 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $84.99 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $42.68 | 2025 | Acthar |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $40.54 | 2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $31.02 | 2024 | Xiidra, Vyzulta |
| Dompe US, INC. | $30.07 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $27.47 | 2025 | Syfovre |
| Coopervision INC. | $27.45 | 2021 | |
| Maculogix, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.